Ahmed Obeidat, MD, PhD, Medical College of Wisconsin, Milwaukee, WI, comments on the use of personalized medicine in multiple sclerosis (MS) treatment, exemplified by shared decision making between clinicians and patients on aspects such as treatment selection. Shared decision making involves understanding patient factors, such as patient preference, while still offering the best course of treatment based on the activity of the disease and prognostic factors. Dr Obeidat believes that this places the patient at ease as they understand the disease and why they are treated with certain agents, ultimately making patients more likely to adhere to treatment plans and increasing the likelihood of better outcomes. As of now, the field of MS does not practice precision medicine, for example using specific biomarkers to determine the most valuable medication in a given scenario. This interview took place at the Consortium of Multiple Sclerosis Centers (CMSC) congress 2022 in Maryland.